METHODS: The medical records of all cirrhotic patients who underwent thoracentesis at the University Hospital (Newark, NJ) over a 12-month period were reviewed, and 66 thoracenteses were recorded. Datapoints extracted from the medical records included peri-procedural vital signs, hemoglobin, platelet count, coagulation studies, whether the patient was taking antiplatelets or anticoagulants, or any blood product transfusions administered periprocedurally. MELD scores were calculated for all patients. Acute and delayed complications were monitored post-procedure. Analyses of two groups was conducted: those who had correction of coagulopathy with transfused blood products, and those who did not have coagulopathy corrected, prior to the thoracentesis. The primary endpoint was the development of a hemorrhagic complication attributable to thoracentesis that required transfusion of blood products or surgical procedures for hemostasis.